“We continued advancement of azenosertib and made solid progress against our strategic goals in the first quarter. The initiation of DENALI Part 2 moves us into a new chapter as a late-stage development company focusing on a significant patient population in platinum-resistant ovarian cancer with limited choices,” said Julie Eastland, Chief Executive Officer of Zentalis (ZNTL). “Our team remains focused on the enrollment and execution of DENALI. Zentalis is financially and organizationally well-positioned to continue advancing azenosertib as a potential treatment option for PROC patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib
- Zentalis Highlights Azenosertib Findings at 2025 AACR
- Promising Potential and Strategic Positioning Justify Buy Rating for Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals: Hold Rating Amid Market Challenges and Awaited Catalysts
- Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty